ARC Medical Devices Inc. controls issued patents and active patent applications for three different, unique patent families that provide protection of ARC’s PERIDAN® products. Patent Family #1 is owned by The University of British Columbia (UBC), is exclusively licensed by ARC Medical Devices Inc., contains issued patents in 35 territories, and will expire in 2022. Patent Family #2 and Patent Family #3 belong to ARC, will expire in 2025 and 2030 respectively, and have patent applications pending in numerous territories. Patent Family #3 already has patents issued in 5 territories.
The following surgeons have joined ARC's Clinical Advisory Board: - Dr. Rudy De Wilde, PhD, ScD, MD.Dr. De Wilde is the Director of Ob/Gyn at Pius Hospital in Germany and a key opinion leader and principal investigator of adhesion clinical studies.- Dr. Brian Kwon, MD, FRCSC, PhD.Dr. Kwon is a surgeon-scientist who is an Associate Professor in the Department of Orthopaedics (UBC), the Associate Director, Clinical Research, for ICORD and the Associate Scientific Director of the Rick Hansen Institute. - Dr. Jian (James) Ye, MD, MSc, FRCSC. Dr. Ye is a cardiovascular surgeon, director of Clinical Research at St. Paul's Hospital and a Clinical Professor of Surgery at UBC.
ARC successfully developed an animal spine (laminectomy) surgical adhesion model and showed compelling efficacy of fucoidan in preventing the formation of spinal adhesions in the spine model.
Fucoidan significantly reduced the formation of cardiac adhesions in an animal cardiac model.
ARC entered into an exclusive distribution and supply agreement with Vedco, Inc. for PERIDAN in the U.S. equine veterinary market.
ARC successfully developed an animalmodel for cardiac surgical adhesions.